Voyager Therapeutics reported second quarter 2026 financial results on August 6, 2026. Collaboration revenue decreased to $3.2 million from $5.2 million in the prior year period due to lower activity under the Neurocrine agreement. Research and development expenses fell to $22.0 million from $31.3 million, while general and administrative expenses dropped to $7.5 million from $10.5 million following 2025 restructuring actions. The company reported a net loss of $24.5 million compared to $33.4 million in the same quarter last year. Cash, cash equivalents, and marketable securities stood at $148.8 million as of June 30, 2026, providing a runway into 2028. Clinically, Voyager expects tau PET imaging data for VY7523 and to begin dosing for gene therapy candidate VY1706 in Q4 2026. The company operates in the biotechnology industry, focusing on developing genetic medicines for neurological diseases.
